Answers are grounded in this paper and cite their sources.
Modern pathology increasingly links tissue-based diagnostics with therapeutic decision-making. Spatial multiomics enables high-resolution interrogation of tumour biology in its native tissue context and can reveal actionable therapeutic targets and spatially defined patient subgroups. Spatially restricted histomorphological features such as tumour budding or direct tumour–adipocyte contact/Stroma AReactive Invasion Front Areas (TAC/SARIFA) illustrate that tissue architecture itself encodes biological information. Spatial omics can dissect the cellular and molecular programmes underlying such patterns, but high costs and analytical complexity require careful study design and pathology-guided tissue selection. Combined with scalable approaches such as immunohistochemistry and computational pathology, spatial profiling can support biomarker discovery, biological interpretation, and clinical translation.
No takes yet. Share an insight, caveat, or question.
Günther et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: